This direct correlation also further confirms that MS patients expressing high GANAB levels belong to the group of patients treated with IFN who have an RS and MRS rank ≥1 (Figure 6) and show disease progression during a one-year observation period after their enrolment. This evidence concerns the gene GANAB and myeloid sarcoma.